Recombinant protein-based COVID-19 vaccine
September 2 , 2021
1308 days
1102
- The Reliance Life Sciences (RLS) will be conducting the trials of its recombinant protein-based COVID-19 vaccine candidate.
- The recombinant protein COVID-19 vaccine uses the spike protein of SARS-CoV-2 as the antigen.
- This helps the human body to recognize and develop a strong booster response to fight off the COVID-19 infection.

Post Views:
1102